SAN DIEGO, Sept. 4, 2019 /PRNewswire/ -- DelMar
Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the
"Company"), a biopharmaceutical company focused on the development
of novel cancer therapies, today announced that the Company has
relocated its headquarters from Vancouver, British Columbia to San Diego, California.
"Our move to the San Diego area
is an important step in the evolution of the Company, as it moves
our headquarters to the United
States, while also providing us with the ability to tap the
local biotechnology talent in San
Diego as we continue to progress through the clinical trial
process of VAL-083. We look forward to taking full advantage
of our new headquarters' location and all of the resources the area
offers."
The Company's new headquarters are located at:
12707 High Bluff Drive
Suite 200
San Diego, CA 92130
Phone: 858-350-4364
About VAL-083
VAL-083 (dianhydrogalactitol) is a "first-in-class",
bifunctional, DNA-targeting agent that introduces inter-strand DNA
cross-links at the N7-position of guanine leading to DNA
double-strand breaks and cancer cell death. VAL-083 has
demonstrated clinical activity against a range of cancers,
including GBM and ovarian cancer in historical clinical trials
sponsored by the U.S. National Cancer Institute (NCI). DelMar
has demonstrated that VAL-083's anti-tumor activity is unaffected
by common mechanisms of chemoresistance, including MGMT,
in cancer cell models and animal studies. Further
details regarding these studies can be found at:
http://www.delmarpharma.com/scientific-publications.html.
About DelMar Pharmaceuticals, Inc.
Located in San Diego,
California, DelMar Pharmaceuticals is focused on the
development and commercialization of new therapies for cancer
patients who have limited or no treatment options. By
focusing on understanding tumor biology and mechanisms of treatment
resistance, the Company identifies biomarkers to personalize new
therapies in indications where patients are failing, or are unable
to tolerate, standard-of-care treatments.
The Company's current pipeline is based around VAL-083, a
"first-in-class", small-molecule chemotherapeutic with a novel
mechanism of action that has demonstrated clinical activity against
a range of cancers, including central nervous system, ovarian and
other solid tumors (e.g. NSCLC, bladder cancer, head & neck) in
U.S. clinical trials sponsored by the NCI. Based on DelMar's
internal research programs and these prior NCI-sponsored clinical
studies, the Company is conducting clinical trials to support the
development and commercialization of VAL-083 to solve significant
unmet medical needs.
VAL-083 is being studied in two collaborator-supported,
biomarker-driven Phase 2 clinical trials for MGMT-unmethylated GBM.
Overcoming MGMT-mediated resistance represents a significant unmet
medical need in the treatment of GBM. In addition, DelMar has
announced the allowance of a separate IND for VAL-083 as a
potential treatment for platinum-resistant ovarian cancer.
Further information on DelMar's clinical trials can be found on
clinicaltrials.gov:
https://www.clinicaltrials.gov/ct2/results?cond=&term=val-083&cntry1=&state1=&recrs
For additional information, please visit
http://delmarpharma.com/; or contact DelMar Pharmaceuticals
Investor Relations: ir@delmarpharma.com / (604) 629-5989.
Safe Harbor Statement
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Any forward-looking statements contained herein
are based on current expectations but are subject to a number of
risks and uncertainties. The factors that could cause actual
future results to differ materially from current expectations
include, but are not limited to, risks and uncertainties relating
to the Company's ability to develop, market and sell products based
on its technology; the expected benefits and efficacy of the
Company's products and technology; the availability of substantial
additional funding for the Company to continue its operations and
to conduct research and development, clinical studies and future
product commercialization; and, the Company's business, research,
product development, regulatory approval, marketing and
distribution plans and strategies. These and other factors
are identified and described in more detail in the Company's
filings with the SEC, including, the Company's Annual Report on
Form 10-K for the year ended June 30,
2018, the Company's Quarterly Reports on Form 10-Q, and the
Company's Current Reports on Form 8-K.
CONTACTS:
Investors:
John
Marco
Managing Director
CORE IR
516-222-2560
johnm@coreir.com
Media:
Jules
Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/delmar-pharmaceuticals-relocates-headquarters-to-san-diego-california-300911339.html
SOURCE DelMar Pharmaceuticals, Inc.